Abstract
To investigate the association of extremes in bodyweight (EBW) and outcomes in patients with acute venous thromboembolism (VTE). Recurrent VTE, major bleeding, and clinically relevant non-major bleeding were compared between patients with bodyweight<60kg, 60-120kg, and>120kg. Consecutive patients enrolled in the Mayo Clinic VTE Registry (03/28/2013-8/31/2019) with acute VTE were followed prospectively. Patient status was assessed in person, by mailing a written questionnaire, or by a scripted phone interview. Among 2577 patients with weight ranging from 27.0kg to 263.2kg, 2123 (82%) had a bodyweight between 60 and 120kg, 223 (8.7%) had bodyweight<60kg, and 230 (8.9%) had bodyweight>120kg. Patients with bodyweight<60kg treated with DOACs had higher 3- and 6-month incidence of major bleeding compared to the bodyweight 60-120kg group (4.4% vs 1.1%, P=.03, and 4.4% vs 1.4%, P=.05, respectively). Patients with bodyweight>120kg and cancer on rivaroxaban had higher VTE recurrence compared to bodyweight 60-120kg group (P=.01). Treatment of acute VTE is associated with a higher incidence of bleeding in patients with bodyweight<60kg. A higher VTE recurrence rate occurred only in cancer patients with bodyweight>120kg on rivaroxaban.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
